Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
psilocybin + fluoxetine
- Development stage
- Phase 2
- Lead developer
- Federal University of Latin American Integration
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
psilocybin + fluoxetine is an investigational combination therapy being studied by the Federal University of Latin American Integration for the treatment of treatment-resistant major depressive disorder (TRD). The treatment regimen involves the administration of standardized *Psilocybe cubensis* mushrooms, which contain the psychedelic compounds psilocybin and psilocin, in conjunction with the selective serotonin reuptake inhibitor (SSRI) fluoxetine. Psilocybin acts as a potent agonist at the serotonin 5-HT2A receptor, facilitating neuroplasticity and therapeutic psychedelic experiences, while fluoxetine inhibits the serotonin transporter (SERT) to increase synaptic serotonin levels. This specific research, conducted under the COGUNILA trial (Phase 2a), aims to determine if concurrent SSRI administration modulates the safety, antidepressant efficacy, or the intensity of the acute psychedelic experience, addressing a critical clinical question regarding the management of patients on conventional antidepressants undergoing psychedelic-assisted psychotherapy.
- Other names
- Psilocybe cubensis mushrooms + fluoxetinepsilocybin-assisted psychotherapy with fluoxetine
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR2A (Serotonin receptor 5-HT2A)HTR2C (5-hydroxytryptamine 2C receptor)SERT (Sodium-dependent serotonin transporter)
Beyond the preview
Go deeper on psilocybin + fluoxetine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on psilocybin + fluoxetine.